VIDEO: Valeda light delivery system improves visual acuity in patients with dry AMD
Click Here to Manage Email Alerts
Key takeaways:
- The Valeda light delivery system helped patients with dry age-related macular degeneration gain five letters of visual acuity.
- Treatment also significantly decreased progression to geographic atrophy.
WASHINGTON — In this Healio video, Jeffry Gerson, OD, FAAO, shares results from the LIGHTSITE III clinical trial, which evaluated photobiomodulation treatment in patients with dry age-related macular degeneration.
According to a poster presented at Optometry’s Meeting, the study evaluated the Valeda light delivery system (LumiThera), which uses three wavelengths of light — 590 nm, 660 nm and 850 nm. Participants received nine treatments over the course of 3 to 5 weeks every 4 months.
“The majority of the patients in the study had intermediate dry AMD,” Gerson, an optometrist at Grin Eye Care in Olathe, Kansas, said. “And what we found was that there was a statistically significant improvement in people gaining five letters of visual acuity.”
There also was a significant decrease in the progression to geographic atrophy, he noted.
“This is an office-based treatment, using different wavelengths of light, that once approved, optometrists can administer in our offices,” Gerson said. “It should be dramatically beneficial for our AMD patients, in helping them to not just maintain their vision but to gain vision.”
Collapse
Gerson J, et al. LIGHTSITE III analysis: 24-month evaluation of multiwavelength photobiomodulation in dry age-related macular degeneration using the Valeda light delivery system. Presented at: Optometry’s Meeting; June 21-24, 2023; Washington.
Read more about
Click Here to Manage Email Alerts